Cyclophilin Inhibitors

被引：49

作者：

Gallay, Philippe A. ^{[1
]}

机构：

[1] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA

来源：

CLINICS IN LIVER DISEASE | 2009年 / 13卷 / 03期

关键词：

Hepatitis C virus (HCV); Cyclophilins; Cyclosporine A derivatives; Inhibitors; Isomerase; HEPATITIS-C-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; ALPHA-2A PLUS RIBAVIRIN; CIS-TRANS ISOMERASE; CYCLOSPORINE-A; PEGINTERFERON ALPHA-2A; INITIAL TREATMENT; PEGYLATED INTERFERON-ALPHA-2B; CELL CYCLOPHILIN; HOMOLOG NINAA;

D O I：

10.1016/j.cld.2009.05.002

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

The percentage of patients chronically infected with hepatitis C virus (HCV) who have reached sustained antiviral response has increased since the introduction of the pegylated interferon-alpha (pIFNa) and ribavirin (RBV) treatment. However, the current standard pIFNa/RBV therapy not only has a low success rate (about 50%) but is often associated with serious side effects. Thus, there is an urgent need for the development of new anti-HCV agents. Cyclophilin (Cyp) inhibitors are among the most promising of the new anti-HCV agents under development. Recent clinical studies demonstrate that Cyp inhibitors are potent anti-HCV drugs, with a novel mechanism of action and efficacy profiles that make them attractive candidates for combination with current and future HCV treatments.

引用

页码：403 / +

页数：16

共 83 条

[1]

Effects of cyclosporin A on hepatitis C virus infection in bone marrow transplant patients [J].

Akiyama, H ;

Yoshinaga, H ;

Tanaka, T ;

Hiruma, K ;

Tanikawa, S ;

Sakamaki, H ;

Onozawa, Y ;

Wakita, T ;

Kohara, M .

BONE MARROW TRANSPLANTATION, 1997, 20 (11) :993-995

[2]

Epidemiology of hepatitis C virus infection [J].

Alter, Miriam J. .

WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (17) :2436-2441

[3]

BANG H, 2001, BIOMED BIOCHIM ACTA, V50, pS137

[4]

BOBARDT M, 2008, 15 INT S HEP C VIR R

[5]

Borel JF, 2002, WIEN KLIN WOCHENSCHR, V114, P433

[6]

Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells [J].

Braaten, D ;

Luban, J .

EMBO JOURNAL, 2001, 20 (06) :1300-1309

[7]

The hydrophobic pocket of cyclophilin is the binding site for the human immunodeficiency virus type 1 Gag polyprotein [J].

Braaten, D ;

Ansari, H ;

Luban, J .

JOURNAL OF VIROLOGY, 1997, 71 (03) :2107-2113

[8]

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients -: A randomized controlled trial [J].

Carrat, F ;

Bani-Sadr, F ;

Pol, S ;

Rosenthal, E ;

Lunel-Fabiani, F ;

Benzekri, A ;

Morand, P ;

Goujard, C ;

Pialoux, G ;

Piroth, L ;

Salmon-Céron, D ;

Degott, C ;

Cacoub, P ;

Perronne, C .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (23) :2839-2848

[9]

COELMONT L, 2007, 14 INT S HEP C VIR G, pO61

[10]

Debio 025, a Cyclophilin Binding Molecule, Is Highly Efficient in Clearing Hepatitis C Virus (HCV) Replicon-Containing Cells When Used Alone or in Combination with Specifically Targeted Antiviral Therapy for HCV (STAT-C) Inhibitors [J].

Coelmont, Lotte ;

Kaptein, Suzanne ;

Paeshuyse, Jan ;

Vliegen, Inge ;

Dumont, Jean-Maurice ;

Vuagniaux, Gregoire ;

Neyts, Johan .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (03) :967-976

← 1 2 3 4 5 6 7 8 9 →